Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

Kevin K Ariën; Leo Heyndrickx; Johan Michiels; Katleen Vereecken; Kurt Van Lent; Sandra Coppens; Betty Willems; Pieter Pannus; Geert A Martens; Marjan Van Esbroeck; Maria E Goossens; Arnaud Marchant; Koen Bartholomeeusen; Isabelle Desombere

doi:10.1038/s41541-022-00459-z

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

NPJ Vaccines. 2022 Mar 8;7(1):35. doi: 10.1038/s41541-022-00459-z.

Authors

Affiliations

¹ Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium. karien@itg.be.
² Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium. karien@itg.be.
³ Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.
⁴ Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.
⁵ SD Epidemiology and Public Health, Sciensano, Brussels, Belgium.
⁶ Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium.
⁷ Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
⁸ Immune response, SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium.

Abstract

We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants in unimmunized infected (group 1), immunised and boosted (group 2) and infected immunised and boosted (group 3) adult individuals. Our observations support the rapid administration of a booster vaccine dose to prevent infection and disease caused by Omicron.